Table 1.
Characteristics of the 17 Included Adult Patients Diagnosed With Diffuse Hemispheric Glioma, H3 G34-mutant
| Patients | Sex | Age (years) | Suspected diganosis | Tumor location | Gadolinium menhancement | Presence of a cyst | Presence of necrotic areas | Restriction of diffusion | Surgical management | Microscopic aspect | Ki67 index | Olig2 staining | TP53 staining | IDH mutation | ATRX loss | EGFR amplification | MGMT methylation | Progression free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 29 | HGG | PO | Yes | Yes | No | - | TR | Monstro | 35% | 0% | 80% | No | Yes | No | Yes | 97 | 99c |
| 2 | F | 25 | HGG | FP | Yes | No | No | - | TR | PNET | 60% | 0% | 80% | No | Yes | No | Yes | 40.8 | 53.4 |
| 3 | F | 23 | MS | FP | No | No | No | Yes(F) | B | PNET | 40% | 0% | 60% | No | - | No | Yes | 9.3 | 11.1 |
| 4 | M | 33 | LE | TI | No | No | No | Yes | PR | PNET | 75% | 0% | 100% | No | Yes | No | Yes | 4.5 | 11.9 |
| 5 | F | 29 | LGG/MS | FPa | No | No | No | Yes | B | PNET | 20% | 0% | 100% | No | Yes | No | - | 5.7 | 50.4 |
| 6 | F | 30 | HGG | FCb | Yes | Yes | Yes | Yes(F) | B | Undiff | 28% | 0%* | 80% | No | No | No | Yes | 9.5 | 27.5 |
| 7 | M | 22 | H/HGG | TI | Yes(F) | No | No | Yes | TR | PNET | 40% | 0% | 100% | No | Yes | Yes | Yes | 23.1 | 28.8 |
| 8 | M | 33 | PCNSL | FCb | Yes(F) | No | No | Yes(F) | B | Oligoid | 60% | 0%* | 100% | No | Yes | No | Yes | 4.9 | 6.3 |
| 9 | M | 21 | H/AVM | FP | - | No | No | - | TR | Monstro | 95% | 0% | 100% | No | Yes | No | Yes | 24 | 30c |
| 10 | M | 19 | LGG | FPb | No | No | No | Yes(F) | B | PNET | 40% | 0% | 100% | No | Yes | Yes | No | 7.1 | 9.0 |
| 11 | F | 37 | LGG | FP | No | No | No | No | B | A-III | 30% | 0%* | 10% | No | Yes | No | Yes | 26.2 | 55.4 |
| 12 | M | 31 | HGG | TIa | Yes(F) | No | No | Yes(F) | B | Undiff | 40% | 0% | 90% | No | - | No | No | 8.7 | 12.4 |
| 13 | M | 29 | A | FPa | Yes(F) | No | No | Yes(F) | B | PNET | 50% | 0% | 90% | No | Yes | - | - | 8.8 | 12.5 |
| 14 | M | 18 | MD | PCb | Yes(F) | No | No | Yes(F) | B | Undiff | 25% | 0% | 40% | No | Yes | - | - | 3.2 | 4.2 |
| 15 | M | 22 | H/HGG | FP | Yes | No | No | Yes | B | PNET | 25% | 0% | 5% | No | Yes | - | - | 0.1 | 0.1 |
| 16 | F | 19 | PCNSL | FP | Yes(F) | No | No | Yes(F) | B | Monstro | 15% | 0% | 90% | No | Yes | No | - | 6.4 | 8.4 |
| 17 | M | 18 | - | - | - | - | - | - | B | Undiff | - | - | - | No | - | No | - | 11.4 | 14.4 |
Sex. F: Female, M: Male;
Initially suspected diagnosis. A: Abscess, AVM: Arterio-venous Malformation, H: Hematoma, HGG: High-grade glioma, LE: Limbic encephalitis, LGG: Low-grade glioma, MD: Metabolic disease, MS: Multiple sclerosis, PCNSL: Primary central nervous system lymphoma;
Tumor location. FC: fronto-callosal, FP: fronto-parietal, PO: parieto-occipital, TI: temporo-insular, a indicates tumors that were only cortical at diagnosis, b indicates midline invasion;
Gadolinium enhancement. (F): Faint;
Restriction of Diffusion. (F): Focal;
Surgical management. B: Biopsy, PR: Partial Resection, TR: Total Resection;
Microscopic aspect. A-III: Grade III Astrocytoma, Monstro: Monstroscellular glioblastoma, Oligoid: Glioblastoma with oligoid morphology, PNET: Glioblastoma with Primitive Neuro-Ectodermic Tumor-like foci, Undiff: Glioblastoma with undifferenciated morphology;
Olig2 staining. * indicates cases containing Olig2-imunopositive reactive glial cells
Overall survival. c indicates patients who are still alive.